Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Differential in vitro effects of targeted therapeutics in primary human liver cancer: importance for combined liver cancer

Fig. 5

Proliferation studies of ICC (HUH28, RBE, SSP25, a-c), ECC (EGI1, CCC5, TFK1, d-f) and HCC/hepatoblastoma (HEP3B, HUH7, HEPG2, g-i) cell lines. Effects of (A) BKM120, (B) Wortmannin (Wort), (C) LY294002 (LY29), and (D) CAL-101 after 0, 24, 48, 72 and 96 h (h). 0 h values were set to 100%. Concentrations of BKM120 are indicated. Shown are the mean values of n = 3–5 independent experiments with each 6–8 replicates. Controls were treated with solvent (DMSO). Significance was tested by one-way ANOVA between the control and treatment groups. *p < 0.05, **p < 0.01, ***p < 0.001 with 95% level of confidence

Back to article page